Clinical trials: Mammary Tumor
HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes…
- Trial name
- PATINA (NCT02947685)
- Testing
- palbociclib, trastuzumab, pertuzumab
- Where
- 108 sites in United States, Australia and 6 more
- Volunteers
- 518 people
- Sponsor
- Alliance Foundation Trials, LLC.
Physical Activity, Breast Cancer
Study of Program Interest "Bouge" to Improve the Daily Physical Activity in Processings Treatment of Non-metastatic Breast Cancer
Evaluate the "Bouge" digital program (smartphone application) to increase the daily physical activity of breast cancer patients
- Conditions
- Physical Activity, Breast Cancer, Mobile Health Apps
- Trial name
- BOUGE CANCER (NCT03674515)
- Testing
- Smartphone equipped with application "bouge" = Coach group
- Where
- 2 sites in France
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
Breast Cancer
Patient-Assisted Compression - Impact on Image Quality and Workflow
This study is being conducted to compare the image quality of breast images obtained using standard (technologist-controlled [TC]) compression and patient-assisted (PA) compression and to evaluate the impact of PA compression on…
- Trial name
- NCT03196635
- Testing
- Patient-Assisted (PA) Breast Compression, Technologist-Controlled (TC) Breast Compression
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- GE Healthcare
Breast Cancer Female, Pain, Postoperative
Analgesic Effect of Adding Thoracic Paravertebral Nerve Blocks to Modified PEC Block in Breast Cancer Surgery
To compare efficacy and safety of adding thoracic paravertebral nerve blocks to modified PEC block versus modified PEC block only in breast cancer surgery.
- Trial name
- NCT04056676
- Testing
- Thoracic paravertebral block under ultrasound guidance, Intraoperative modified PEC block, GA with ETT
- Where
- Thailand
- Volunteers
- 100 people
- Sponsor
- Mahidol University
Mammographic Breast Density
Study of the Effects of Cyclodynon on Reducing the Cumulative Risk of Breast Cancer Development in a Female Aged 40-52
Increased mammographic density of mammary gland tissues and hyperprolactinaemia are regarded as one of the risk factors for the development of breast cancer in women aged 40 to 52 years, which necessitates closer monitoring of…
- Trial name
- BIO-CYCL (NCT04498013)
- Testing
- Cyclodynon, Lifestyl modification
- Where
- Ukraine
- Volunteers
- 150 people
- Sponsor
- Dr. Struk Tetiana
Breast Cancer
Circulating Tumor DNA and Immunophenotyping as Potential Biomarkers With Regional Nodal Irradiation for Breast Cancer
This study will assess how radiation affects the patterns of circulating tumor deoxyribonucleic acid (ctDNA) and immune cells (T cells) during radiation treatment in patients with breast cancer.
- Trial name
- NCT04308720
- Where
- United States
- Volunteers
- 217 people
- Sponsor
- Mayo Clinic
Breast Cancer
A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients
The purpose of this study is to test whether patients with breast cancer who are being treated with non-anthracycline trastuzumab therapy can safely be monitored for heart related side effects less often than usual.
- Trial name
- NCT03983382
- Testing
- Left Ventricular Ejection Fraction
- Where
- 8 sites in United States
- Volunteers
- 190 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adenocarcinoma
Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast
The primary objectives of this study were to assess the safety and tolerability of intravenously (i.v.) administered 186Rhenium (186Re)-labelled bivatuzumab and to investigate the biodistribution and pharmacokinetics of…
- Trial name
- NCT02204046
- Testing
- BIWA 4
- Volunteers
- 9 people
- Sponsor
- Boehringer Ingelheim
Hormone Receptor-Positive, HER2-Negative, Node Positive Breast Cancer
Neoadjuvant Letrozole in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Node Positive, Early-Stage Breast Cancer.
The goal of this clinical trial is to learn whether letrozole, a hormone therapy drug, is effective in treating early-stage, hormone receptor-positive, HER2-negative breast cancer that has spread to nearby lymph nodes in…
- Trial name
- NELOPHER (NCT07394946)
- Testing
- Letrozole
- Where
- Pakistan
- Volunteers
- 126 people
- Sponsor
- Cancer Care Hospital & Research Centre Foundation, Lahore
Younger Breast Cancer Survivors
A Mindfulness Meditation-Based Intervention for Younger Breast Cancer Survivors
Younger women with breast cancer experience substantially greater distress and depressive symptoms than older women. These symptoms can hamper recovery and healthy behaviors that can reduce the risk of recurrence and/or other…
- Trial name
- NCT01558258
- Testing
- Mindful Awareness practices (MAPs)
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Triple-Negative Breast Neoplasm
Tracking Triple-negative Breast Cancer Evolution Through Therapy
A prospective multicentre study which aims to examine the relationship between intratumour heterogeneity (ITH) and pathological response to neoadjuvant chemotherapy in patients with histological confirmation of triple-negative…
- Trial name
- TRACERX-TNBC (NCT03077776)
- Testing
- Biopsy, Biopsy (optional), Biopsy (metastatic)
- Where
- 10 sites in France
- Volunteers
- 149 people
- Sponsor
- UNICANCER
Breast Cancer, Osteoporosis
Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98
RATIONALE: Diagnostic procedures, such as bone mineral density testing and x-ray, help measure bone loss in women receiving treatment for breast cancer. The test results may help doctors plan better treatment.
- Trial name
- NCT00369850
- Testing
- laboratory biomarker analysis, Dual energy X-ray absorptiometry (DEXA), Spine X-ray
- Where
- 16 sites in Australia, France and 6 more
- Volunteers
- 458 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer
Gene expression, the transfer of the genetic code into cellular proteins is one of the most fundamental processes in living cells.
- Trial name
- NCT03430024
- Testing
- Association of Myosin VI with oestrogen receptor
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Maidstone & Tunbridge Wells NHS Trust
Breast Neoplasms
Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer
This is an international, multicentre, double-blind, controlled, randomized phase II study comparing the efficacy and safety of fulvestrant in combination with palbociclib versus fulvestrant plus placebo in postmenopausal women…
- Trial name
- FLIPPER (NCT02690480)
- Testing
- PD-0332991 (Palbociclib), Fulvestrant
- Where
- 32 sites in Ireland, Spain
- Volunteers
- 189 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer
Genome Sequencing in Refractory Breast Cancer to Molecular Targeted Therapy and Young Breast Cancer
The purpose of this study is to investigate and analyse genomic profiles in patient with breast cancer who failed standard treatment, refractory and young breast cancer.
- Trial name
- NCT02597179
- Where
- South Korea
- Volunteers
- 350 people
- Sponsor
- Samsung Medical Center
Breast Cancer (Triple Negative Breast Cancer (TNBC))
Performance of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer
The goal of this observational, retrospective, non interventional study is to learn about the efficacy of an Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer (TNBC).
- Trial name
- NEO-AgeTN (NCT07687446)
- Testing
- Non interventional study
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Melanoma, Breast Cancer
Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)
Coxsackie A21 (CVA21) virus is to be administered by IV infusion to patients with Stage 4 melanoma, prostate and breast cancer. This is a dose escalation, safety study.
- Conditions
- Melanoma, Breast Cancer, Prostate Cancer
- Trial name
- PSX-X04 (NCT00636558)
- Testing
- CVA21
- Where
- 2 sites in Australia
- Volunteers
- 8 people
- Sponsor
- Viralytics
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Pts w/Low Risk, Hormone Responsive Brst Ca
This phase II trial tests how well accelerated partial breast irradiation (APBI) delivered once per day works in ensuring an acceptable breast appearance in patients with low risk, hormone responsive breast cancer.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
- Trial name
- NCT06008158
- Testing
- Accelerated Partial Breast Irradiation
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- City of Hope Medical Center
Breast Neoplasms
Post-Treatment Surveillance in Breast Cancer: Bringing CER to the Alliance
Nearly three million living women have survived breast cancer. Physicians rely on clinical practice guidelines to make decisions on follow-up care.
- Trial name
- NCT02171078
- Where
- United States
- Volunteers
- 34,359 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Breast Cancer
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)
This is an open label, phase II study evaluating the efficacy and safety of trastuzumab combined with oral chemotherapy (capecitabine or vinorelbine) in patients with HER-2 positive stage I breast cancer.
- Trial name
- NCT04922008
- Testing
- capecitabine and trastuzumab, vinorelbine and trastuzumab
- Volunteers
- 356 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.